中国创新力量:全球首款阿立哌唑微球开启精分治疗“月时代”

证券市场周刊
12 May

在精神分裂症治疗领域,阿立哌唑占据着十分重要的地位。作为多巴胺D2和5-HT1A受体的部分激动剂,以及5-HT2A受体的拮抗剂,阿立哌唑能够根据大脑内的多巴胺环境调节神经传递,从而稳定多巴胺神经系统。这种作用机制使得阿立哌唑在改善精神分裂症的阳性和阴性症状方面表现优异,并且减少了传统药物可能导致的体重增加和运动障碍等不良反应。值得一提的是,精神分裂症患者的预期寿命较一般人群缩短约15年,其中心血管...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10